Panitumumab in RAS Wild-Type Left-Sided mCRC: Evidence Synthesis
Analysis Oncology Pharmacy Confirmatory Grade: Low
Kwiatkowska L, Szczuko M
Sep 15, 2026 · Published in: International Journal of Molecular Sciences
Panitumumab extends survival in metastatic colorectal cancer with precision therapy advances.
Neoadjuvant chemoimmunotherapy plus afatinib yields high pathologic response in head and neck cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Wei Z, Chen H, Wang D, et al.
Sep 12, 2026 · Published in: Journal for Immunotherapy of Cancer
New chemoimmunotherapy regimen shows promise for head and neck cancer.
Cisplatin adds to, does not synergize with, radiation lymphocyte apoptosis
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Sak A, Mladenov E, Alberti Y, et al.
Sep 6, 2026 · Published in: Radiation Oncology (London, England)
Cisplatin adds to radiation's apoptotic impact on cancer patients' lymphocytes.
Chitosan Nanoparticles for Thyroid Cancer: Preclinical Promise, No Clinical Data
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Alyami HS, Ahmadi NA
Sep 5, 2026 · Published in: Medicine
Chitosan-based nanoparticles could revolutionize thyroid cancer treatment with targeted delivery.
Adjuvant Therapy After Neoadjuvant Immunochemotherapy Improves Survival in Resected ESCC
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Zhang X, Gao H, Cao J, et al.
Sep 3, 2026 · Published in: Frontiers in Immunology
Postoperative adjuvant therapy enhances survival for ESCC after neoadjuvant treatment.
Talquetamab Infection Burden: Half Any-Grade, One-Fifth Severe
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Sep 3, 2026 · Published in: Frontiers in Immunology
Talquetamab raises infection concerns in RRMM patients.
Pharmacist-Integrated Multidisciplinary Care in Pregnancy-Associated Breast Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Liu H, Jin J, Deng Y, et al.
Aug 28, 2026 · Published in: Frontiers in Oncology
Pharmacists enhance pregnancy-related chemotherapy care for breast cancer.
SCLC 2026: Consolidation Durvalumab, Maintenance Lurbinectedin, and Tarlatamab Reshape Care
Analysis Oncology Pharmacy Confirmatory Grade: Moderate
Lalla M, Dhillon P, Polat BE, et al.
Aug 20, 2026 · Published in: Lung
New therapeutic advances redefine small cell lung cancer management.
Perioperative Enfortumab Vedotin plus Pembrolizumab Cost-Effective in Cisplatin-Ineligible MIBC
Analysis Oncology Pharmacy Confirmatory Grade: Low
Hill-McManus D, Lai Y, Bensimon AG, et al.
Aug 18, 2026 · Published in: Journal of Medical Economics
Pembrolizumab plus enfortumab vedotin stands out as cost-effective for bladder cancer.
Metronomic Doxorubicin Plus Low-Dose Radiation in Preclinical Breast Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Abdelrahman IY, Saif-Elnasr M, Attia ZR, et al.
Aug 13, 2026 · Published in: Cell Biochemistry and Function
Metronomic doxorubicin plus low-dose radiation shows promise for breast cancer.
New CAR-T Therapy Shows Promise for Relapsed B-ALL
Analysis Oncology Pharmacy
Hu E, Johnson S, Abinsay T, et al.
Aug 10, 2026 · Published in: The Annals of Pharmacotherapy
Obecabtagene autoleucel shows promising results in tough-to-treat B-ALL cases.
Intracranial B7-H3 CAR-T Shows Early Promise in Recurrent Glioblastoma
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Zhang Y, Chi X, Feng R, et al.
Aug 7, 2026 · Published in: Nature Medicine
CAR-T cell therapy offers new hope for recurrent glioblastoma.
Talquetamab Efficacy in Multiple Myeloma Shown Over 3 Years
Analysis Oncology Pharmacy
Rasche L, Schinke C, Touzeau C, et al.
Aug 6, 2026 · Published in: Blood
Long-term talquetamab offers hope for relapsed/refractory multiple myeloma.
Seizure Prophylaxis in Aneurysmal SAH: New Guidelines
Analysis Oncology
Rowe AS, Zafar SF, Tesoro E, et al.
Aug 5, 2026 · Published in: Neurocritical Care
Seizure prophylaxis in aneurysmal SAH: ASM or not?
Glucocorticoid Use Impacts NSCLC Survival on ICIs
Analysis Oncology
Lee DE, Lim G, Ko M, et al.
Aug 5, 2026 · Published in: Clinical Pharmacology and Therapeutics
High-dose glucocorticoids may harm NSCLC patients on ICIs.